Tanimilast Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Tanimilast Growth

1) Large COPD population initially created blockbuster potential

COPD remains a massive commercial opportunity globally:

• ~390 million people live with COPD worldwide
• COPD is the 3rd leading cause of death globally (WHO)
• Millions remain uncontrolled despite LABA/LAMA/ICS triple therapy

Tanimilast was specifically being positioned for COPD patients with chronic bronchitis phenotype and frequent exacerbations, a high-cost subgroup with significant hospitalization burden. Even modest market penetration in this segment could have created meaningful sales potential.

2) Differentiated inhaled PDE4 mechanism vs oral roflumilast

One of the biggest early growth drivers was its differentiated delivery model. Unlike oral roflumilast (which has been limited by GI side effects such as diarrhea, nausea, and weight loss), Tanimilast was designed as an inhaled PDE4 inhibitor, enabling:

• Direct lung delivery
• Lower systemic exposure
• Potentially better tolerability
• Easier add-on use with triple therapy

This was viewed as a major competitive advantage in earlier development.

3) Strong Phase II data initially supported late-stage optimism

Earlier Phase II studies showed encouraging biomarker reductions and lung inflammation control:

• Reduced sputum inflammatory biomarkers
• Improved anti-inflammatory activity in chronic bronchitis patients
• Favorable tolerability profile compared with oral PDE4 inhibitors

These early studies helped move the drug into Phase III and initially supported expectations that it could become a meaningful add-on COPD therapy.

4) Large unmet need in exacerbation prevention

Frequent COPD exacerbations remain one of the biggest unmet needs in respiratory medicine because they drive:

• Hospital admissions
• Mortality risk
• Rising healthcare costs

This was particularly attractive because biologics such as Dupixent and Nucala mainly target narrower eosinophilic subsets, while Tanimilast was being developed for broader chronic bronchitis populations.

5) Phase III PILASTER failure severely damaged commercial outlook

This became the biggest negative inflection point. In September 2025, Chiesi announced that the Phase III PILASTER trial failed to meet both primary and secondary endpoints, meaning Tanimilast did not significantly reduce exacerbations in COPD patients. No major safety concerns were reported, but efficacy failure largely eliminated near-term commercialization potential.

Tanimilast Recent Developments

In January 2026, NICE approved dupilumab as the first biologic treatment for certain types of COPD, targeting both symptoms and underlying causes of the disease.  
“Tanimilast Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of Tanimilast for potential indication like Chronic obstructive pulmonary disease, Allergic asthma, and Asthma in the 7MM. A detailed picture of Tanimilast’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Tanimilast for potential indications. The Tanimilast market report provides insights about Tanimilast’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Tanimilast performance, future market assessments inclusive of the Tanimilast market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Tanimilast sales forecasts, along with factors driving its market.

Tanimilast Drug Summary

Tanimilast is an investigational, inhaled phosphodiesterase-4 inhibitor developed by Chiesi Farmaceutici S.p.A. for the treatment of Chronic Obstructive Pulmonary Disease and other inflammatory respiratory disorders. Delivered via inhalation, tanimilast is designed to provide potent anti-inflammatory activity directly in the lungs while minimizing the systemic side effects commonly associated with oral PDE4 inhibitors such as Roflumilast. It works by inhibiting PDE4 enzymes, leading to increased intracellular cyclic AMP levels and suppression of inflammatory cell activity involved in COPD exacerbations. Clinical studies have shown reductions in airway inflammation biomarkers and potential benefits in preventing exacerbations, particularly in patients with chronic bronchitis and eosinophilic inflammation. Tanimilast remains in late-stage clinical development and is being evaluated as an add-on therapy to standard inhaled maintenance treatments in COPD. The report provides Tanimilast’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Tanimilast Market Report

The report provides insights into:

• A comprehensive product overview including the Tanimilast MoA, description, dosage and administration, research and development activities in potential indication like Chronic obstructive pulmonary disease, Allergic asthma, and Asthma.
• Elaborated details on Tanimilast regulatory milestones and other development activities have been provided in Tanimilast market report.
• The report also highlights Tanimilast‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Tanimilast market report also covers the patents information, generic entry and impact on cost cut.
• The Tanimilast market report contains current and forecasted Tanimilast sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Tanimilast market report also features the SWOT analysis with analyst views for Tanimilast in potential indications.

Methodology

The Tanimilast market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Tanimilast Analytical Perspective

• In-depth Tanimilast Market Assessment

This Tanimilast sales market forecast report provides a detailed market assessment of Tanimilast for potential indication like Chronic obstructive pulmonary disease, Allergic asthma, and Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Tanimilast sales data uptil 2034.

• Tanimilast Clinical Assessment

The Tanimilast market report provides the clinical trials information of Tanimilast for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Tanimilast Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Tanimilast Market Potential & Revenue Forecast

• Projected market size for the Tanimilast and its key indications
• Estimated Tanimilast sales potential (Tanimilast peak sales forecasts)
• Tanimilast Pricing strategies and reimbursement landscape

Tanimilast Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Tanimilast Market positioning compared to existing treatments
• Tanimilast Strengths & weaknesses relative to competitors

Tanimilast Regulatory & Commercial Milestones

• Tanimilast Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Tanimilast Clinical Differentiation

• Tanimilast Efficacy & safety advantages over existing drugs
• Tanimilast Unique selling points

Tanimilast Market Report Highlights

• In the coming years, the Tanimilast market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Tanimilast companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Tanimilast’s dominance.
• Other emerging products for Chronic obstructive pulmonary disease, Allergic asthma, and Asthma are expected to give tough market competition to Tanimilast and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Tanimilast in potential indications.
• Analyse Tanimilast cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Tanimilast sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Tanimilast in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Tanimilast? How strong is Tanimilast’s clinical and commercial performance?
• What is Tanimilast’s clinical trial status in each individual indications such as Chronic obstructive pulmonary disease, Allergic asthma, and Asthma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Tanimilast Manufacturers?
• What are the key designations that have been granted to Tanimilast for potential indications? How are they going to impact Tanimilast’s penetration in various geographies?
• What is the current and forecasted Tanimilast market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Tanimilast in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Tanimilast for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Tanimilast? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.